VBI Other Stockholder Equity vs Net Invested Capital Analysis
VBIV Stock | USD 0.57 0.03 5.00% |
VBI Vaccines financial indicator trend analysis is much more than just breaking down VBI Vaccines prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether VBI Vaccines is a good investment. Please check the relationship between VBI Vaccines Other Stockholder Equity and its Net Invested Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
Other Stockholder Equity vs Net Invested Capital
Other Stockholder Equity vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of VBI Vaccines Other Stockholder Equity account and Net Invested Capital. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between VBI Vaccines' Other Stockholder Equity and Net Invested Capital is -0.08. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of VBI Vaccines, assuming nothing else is changed. The correlation between historical values of VBI Vaccines' Other Stockholder Equity and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of VBI Vaccines are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Other Stockholder Equity i.e., VBI Vaccines' Other Stockholder Equity and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | -0.08 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Other Stockholder Equity
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from VBI Vaccines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into VBI Vaccines current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.At this time, VBI Vaccines' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to climb to about 35.9 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.76) in 2024.
2023 | 2024 (projected) | Non Recurring | 5.7M | 5.0M | Reconciled Depreciation | 2.0M | 1.6M |
VBI Vaccines fundamental ratios Correlations
Click cells to compare fundamentals
VBI Vaccines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
VBI Vaccines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Total Stockholder Equity | 88.3M | 171.7M | 143.9M | 64.2M | 7.5M | 7.2M | |
Property Plant And Equipment Net | 10.2M | 10.7M | 11.0M | 12.3M | 11.9M | 21.9M | |
Net Debt | (29.4M) | (92.9M) | (89.9M) | (10.4M) | 29.4M | 30.8M | |
Retained Earnings | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (582.4M) | (553.3M) | |
Cash | 44.2M | 93.8M | 121.7M | 62.6M | 23.7M | 28.9M | |
Non Current Assets Total | 75.2M | 77.3M | 80.0M | 77.4M | 50.7M | 42.9M | |
Non Currrent Assets Other | 2.1M | 2.2M | 4.6M | 4.7M | 1.2M | 1.0M | |
Cash And Short Term Investments | 44.2M | 119.1M | 121.7M | 62.6M | 23.7M | 31.5M | |
Common Stock Shares Outstanding | 4.0M | 7.3M | 8.5M | 8.6M | 15.6M | 16.4M | |
Liabilities And Stockholders Equity | 122.2M | 209.4M | 210.3M | 155.1M | 87.0M | 73.5M | |
Other Current Assets | 450K | 1.3M | 2.2M | 8.4M | 2.8M | 2.9M | |
Other Stockholder Equity | 66.4M | 75.5M | 81.6M | 90.0M | 107.4M | 112.8M | |
Total Liab | 33.9M | 37.7M | 66.4M | 90.9M | 79.4M | 83.4M | |
Property Plant And Equipment Gross | 11.7M | 12.3M | 19.3M | 23.6M | 22.3M | 27.7M | |
Total Current Assets | 47.0M | 132.0M | 130.3M | 77.7M | 36.2M | 33.0M | |
Total Current Liabilities | 29.8M | 17.3M | 32.6M | 36.9M | 75.7M | 79.5M | |
Accounts Payable | 1.1M | 3.7M | 4.3M | 13.0M | 6.4M | 6.8M | |
Net Receivables | 201K | 77K | 8K | 94K | 1.3M | 1.3M | |
Non Current Liabilities Total | 4.2M | 20.3M | 33.8M | 54.0M | 3.7M | 3.5M | |
Accumulated Other Comprehensive Income | (752K) | 1.3M | (1.6M) | 21.4M | 28.3M | 29.7M | |
Other Assets | 620K | 2.2M | 1.3M | 1.4M | 1.0 | 0.95 | |
Short Long Term Debt Total | 14.8M | 944K | 31.8M | 52.2M | 53.0M | 55.7M | |
Inventory | 1.1M | 2.2M | 2.6M | 6.6M | 8.5M | 8.9M | |
Other Current Liab | 12.9M | 12.4M | 26.9M | 22.6M | 6.7M | 6.2M | |
Short Term Debt | 14.8M | 944K | 839K | 972K | 51.7M | 54.3M | |
Common Stock Total Equity | 285.0M | 403.5M | 442.2M | 442.3M | 508.7M | 260.5M | |
Common Stock | 285.0M | 403.5M | 442.2M | 442.3M | 454.2M | 247.1M | |
Net Tangible Assets | 25.3M | 107.3M | 79.5M | 3.7M | 4.2M | 4.0M | |
Intangible Assets | 60.8M | 62.2M | 62.1M | 58.3M | 36.5M | 47.5M | |
Property Plant Equipment | 11.7M | 10.7M | 11.0M | 12.3M | 14.1M | 14.8M | |
Other Liab | 3.4M | 3.4M | 2.9M | 2.7M | 3.1M | 2.7M | |
Short Long Term Debt | 1.6M | 1.1M | 14.8M | 50.8M | 58.4M | 61.3M | |
Current Deferred Revenue | 882K | 255K | 526K | 409K | 10.9M | 11.4M | |
Capital Surpluse | 66.4M | 75.5M | 81.6M | 90.0M | 103.5M | 75.2M | |
Good Will | 8.3M | 2.2M | 2.3M | 2.1M | 1.1M | 1.1M | |
Retained Earnings Total Equity | (262.4M) | (308.6M) | (378.4M) | (489.6M) | (440.6M) | (418.6M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for VBI Stock analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Transaction History View history of all your transactions and understand their impact on performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.03) | Revenue Per Share 0.558 | Quarterly Revenue Growth 1.911 | Return On Assets (0.29) | Return On Equity (2.59) |
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.